Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Person › Details

Thomas Lingelbach (Intercell AG (VSE: ICLL))

Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)

 

Organisations Organisation Intercell AG (VSE: ICLL)
  Today Valneva Austria GmbH
  Group Valneva (Group)
  Former/major organisation Chiron Behring GmbH & Co. KG
  Today Novartis Vaccines and Diagnostics GmbH
  Group GlaxoSmithKline (GSK) (Group)
Products Product vaccine
  Product 2 vaccine technology
     

Intercell AG. (6/10/11). "Press Release: Intercell 2011 Annual Shareholders Meeting – All Resolutions Approved".

Report on the annual shareholders meeting and announcement according to Para 82 Section 9 Austrian Stock Exchange Act in connection with Para 2 Section 1 and Para 3 Section 1 Publication Directive regarding the authorization to repurchase own shares

Vienna, June 10, 2011 - Intercell AG (Vienna Stock Exchange, ICLL) today announced that all proposed resolutions were approved by the Annual Shareholders Meeting held today. A total of approximately 28% of the outstanding share capital of Intercell AG was represented in the meeting.

Announcement regarding authorization to repurchase own shares:

Amendment of the authorization granted by the shareholders' meeting on June 25, 2010, for a share repurchase program by adjusting the equivalent to be paid for treasury shares. The authorization from now on reads as follows:

The management board is authorized according to section 65 para 1 subpara 8 Stock Corporation Act to purchase within the legal limits treasury shares within a duration of 30 months from the date of the resolution, that is June 25, 2010 at a minimum equivalent of Euro 4.00 per share and a maximum equivalent of Euro 30.00 per share. The management board shall be further authorized a) to use treasury shares to serve stock options granted to employees, executives and members of the management board of the Company or an undertaking affiliated with it and/or members of the supervisory board of the Company or an undertaking affiliated with it, b) to sell treasury shares in accordance with section 65 para 1 b Stock Corporation Act at any time via the stock exchange or by a public offer, or c) with the consent of the supervisory board to resolve on another way of conveying of the treasury shares than on the stock exchange or by a public offer under exclusion of the subscription rights of existing shareholders.

The further resolutions included:

> Discharge of the members of the management board for the business year 2010
> Discharge of the members of the supervisory board for the business year 2010
> Remuneration for the members of the supervisory board for the business year 2010
> Election of two members to the supervisory board, Alexander von Gabain and Thomas Szucs
> Providing for the grant of stock options as remuneration to members of the Company's supervisory board
> Authorization of the management board to resolve with the consent of the supervisory board on a conditional capital increase for the purpose of granting share options to employees
> Election of the auditor and the group auditor for the business year 2011

At the meeting Intercell's Management Team (CEO Thomas Lingelbach, CFO Reinhard Kandera and CBO Staph Leavenworth Bakali) reported on the business year 2010 including the financial results and presented an overview on the business strategy and recent achievements in 2011. The presentation to the shareholders is available at the Company's website www.intercell.com.

   
Record changed: 2020-07-24

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px


More documents for Thomas Lingelbach


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top